<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35446392</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-3265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
          <ISOAbbreviation>Clin Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The need for new treatments targeting MPNST: the potential of strategies combining MEK inhibitors with antiangiogenic agents.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">clincanres.3760.2021</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-21-3760</ELocationID>
        <Abstract>
          <AbstractText>Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are aggressive soft tissue sarcomas that represent an important clinical challenge, particularly given their strong tendency to relapse and metastasize, and their relatively poor response to conventional therapies. To date, targeted, non-cytotoxic treatments have demonstrated limited clinical success with MPNSTs, highlighting the need to explore other key pathways in order to find novel, improved therapeutic approaches. Here, we review evidence supporting the crucial role of the RAS/MEK/ERK pathway and angiogenesis in MPNST pathogenesis, and we focus on the potential of therapies targeting these pathways to treat this disease. We also present works suggesting that the combination of MEK inhibitors and anti-angiogenic agents could represent a promising therapeutic strategy to manage MPNSTs. In support of this notion, we discuss the preclinical rational and clinical benefits of this combination therapy in other solid tumor types. Finally, we describe other emerging therapeutic approaches that could improve patient outcomes in MPNSTs, such as immune-based therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gonzalez-Muñoz</LastName>
            <ForeName>Teresa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Spanish National Cancer Research Centre, Madrid, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>AeRang</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Children's National Hospital, Washington, DC, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ratner</LastName>
            <ForeName>Nancy</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peinado</LastName>
            <ForeName>Héctor</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-4256-3413</Identifier>
            <AffiliationInfo>
              <Affiliation>Spanish National Cancer Research Centre, Madrid, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Cancer Res</MedlineTA>
        <NlmUniqueID>9502500</NlmUniqueID>
        <ISSNLinking>1078-0432</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35446392</ArticleId>
        <ArticleId IdType="doi">10.1158/1078-0432.CCR-21-3760</ArticleId>
        <ArticleId IdType="pii">694663</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
